Takeover of Medarex lifts shares of antibody companies

Bristol-Myers Squibb’s decision to acquire Medarex Inc for $2.1 billion has lifted the shares of antibody companies in both the US and Europe including that of Genmab A/S which was founded in 1999 on the basis of Medarex technology.